Clinical Trials Sponsored by Astellas Pharma Europe Ltd.

Total 205 results

Astellas Pharma Europe Ltd.

Completed

Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients (CHORUS)

Kidney Transplantation

Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Poland, Portugal, Romania, Serbia, Spain, Taiwan, Thailand, United Kingdom, Vietna...
Astellas Pharma Europe Ltd.

Completed

Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis

Chronic Kidney Disease (CKD)

Sweden
Astellas Pharma Europe Ltd.

Completed

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice (BELIEVE)

Urologic Diseases | Overactive Bladder | Urinary Bladder Diseases | Urgency Incontinence | Urinary Bladder Overactive

Czechia, Denmark, Greece, Ireland, Slovakia, Spain, Sweden, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment (ELEVATE)

Non-diabetic Painful Peripheral Polyneuropathy | Postherpetic Neuralgia (PHN) | Peripheral Nerve Injury (PNI)

Armenia, Austria, Belarus, Belgium, Bulgaria, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Romania, Russian Federation, Slovakia, Slovenia, Spain, Sweden, Turkey, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
Astellas Pharma Europe Ltd.

Terminated

To Validate an Analytical Method to Measure Concentration of Tacrolimus in Blood Taken From Finger Pricks

Validation | Dried Blood Spot | Transplant Patients

France, United Kingdom
Astellas Pharma Europe Ltd.

Completed

Observation of the Use of QUTENZA™ in Standard Clinical Practice (ASCEND)

Peripheral Neuropathic Pain

Austria, Greece, Italy, Portugal, Spain, Switzerland, United Kingdom
Astellas Pharma Europe Ltd.

Completed

Vesitirim™ in Men Postmarketing Observational Study (VIM)

Overactive Bladder (OAB) | Lower Urinary Tract Symptoms (LUTS)

Ireland
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the ePidemiology of anEmia Associated With chroNic Kidney Disease in Patients in Primary Care Using The Stockholm CREAtinine Measurement (SCREAM) Register

Chronic Kidney Disease

Sweden
Astellas Pharma Europe Ltd.

Completed

A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Czechia, France, Italy, Poland, United Kingdom
Astellas Pharma Europe Ltd.

Terminated

A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients (PROGRESSION)

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Belgium, France, Germany, Poland, Spain, United Kingdom
Astellas Pharma Europe Ltd.

Completed

Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Spain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
Astellas Pharma Europe Ltd.

Completed

A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant (ADDRESS)

Liver Transplant | Kidney Transplant

Italy, Spain, Belgium, Germany, Latvia, Canada, Korea, Republic of, Czechia, Austria, Finland, Belarus, Estonia, France, Hungary, Ireland, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Sweden, Switzerland, United...
Astellas Pharma Europe Ltd.

Completed

A Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients (MITRA)

Liver Transplantation | Kidney Transplantation

France, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation (OPTION)

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Belgium, France, Germany, Poland, Spain, United Kingdom
Astellas Pharma Europe Ltd.

Completed

Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) (PROFILE)

Inflammatory Bowel Disease (IBD) | Clostridium Difficile Infection (CDI)

Austria, France, Greece, Italy, Poland, Russian Federation, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Astellas Pharma Europe Ltd.

Terminated

A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease (EFFECT)

Metastatic Prostate Cancer

Netherlands
Astellas Pharma Europe Ltd.

Terminated

An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics

Overactive Bladder | Healthy Subjects

Netherlands
Astellas Pharma Europe Ltd.

Active, not recruiting

Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Liver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine Transplantation

Belgium, Czechia, France, Germany, Italy, Poland, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Survey About Trade-offs When Choosing Menopause Treatments

Moderate to Severe Vasomotor Symptoms

United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Survey About Hot Flashes in Women Going Through the Menopause

Vasomotor Symptoms | Menopause

United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the Disease Trajectories Until Progression or Death

Prostate Cancer

Sweden
Astellas Pharma Europe Ltd.

Completed

Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food

Herpes Zoster | Herpes Genitalis

France
Astellas Pharma Inc
Boehringer Ingelheim; Astellas Pharma Europe Ltd.

Completed

A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.

Benign Prostatic Hyperplasia
Astellas Pharma Europe Ltd.
Medivation, Inc.

Completed

European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) (PREMISE)

Metastatic Castration Resistant Prostate Cancer

Czechia, Netherlands, Denmark, Italy, Austria, Belgium, Bulgaria, France, Germany, Greece, Hungary, Ireland, Portugal, Slovenia, Spain, United Kingdom
Astellas Pharma Europe Ltd.
Cubist Pharmaceuticals LLC

Terminated

A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System (FREEDOM)

Clostridium Difficile

Spain, France, Germany, Greece, Denmark, Austria, Poland
Astellas Pharma Europe B.V.

Completed

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (Crocodile)

Neurogenic Detrusor Overactivity

Belgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

Overactive Bladder | Neurogenic Detrusor Overactivity

Denmark, Poland
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee (OAK)

Osteoarthritis of the Knee | Chronic Lower Back Pain

Belgium, Czechia, Germany, Hungary, Spain, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain

Endometriosis

Belgium, Bulgaria, Germany, Hungary, Japan, Poland, Romania, Ukraine, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Pediatric | Neurogenic Detrusor Overactivity

United States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease (ALBUM)

Type 2 Diabetes | Chronic Kidney Disease

Spain, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin (IMPRESSION)

Type 2 Diabetes Mellitus

Russian Federation
Astellas Pharma Europe B.V.

Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (SYNERGY)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

United States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands and more
Astellas Pharma Europe B.V.

Completed

A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety (MOBILE)

Neuropathic Pain | Post-Herpetic Neuralgia (PHN) | Painful Diabetic Peripheral Neuropathy (PDPN)

Czechia, Germany, Poland, United Kingdom
Astellas Pharma Europe B.V.

Terminated

A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy (BiGARD)

NSAID-induced Gastropathy

Russian Federation
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

Healthy Subjects | Pharmacokinetics of ASP6294

United Kingdom
Astellas Pharma Europe B.V.

Completed

First-in-human: Single Ascending Dose, Food Effect, Drug-drug Interaction, Multiple Ascending Dose, Proof of Pharmacology

Healthy Volunteers

United Kingdom, Germany
Astellas Pharma Europe B.V.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205

Healthy Subjects | Pharmacokinetics of ASP2205

United Kingdom
Astellas Pharma Europe B.V.

Completed

EC905 Pharmacokinetic Profile Study

Healthy | Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia | Phase 1

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects (MAD)

Healthy Volunteers | Pharmacokinetics of ASP7962

United Kingdom
Astellas Pharma Europe B.V.

Terminated

To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis (DAISY)

Clostridium Difficile

France, Germany, Netherlands, Spain
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males

Pharmacokinetics of ASP8477 | Pharmacodynamics of ASP8477

France, Belgium
Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

Healthy Subjects | Pharmacokinetics | Drug-Drug Interaction (DDI)

Germany
Astellas Pharma Europe B.V.

Completed

A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans

Tolerability | Safety | Pharmacokinetics of ASP7962

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Interaction Between ASP1707 and Itraconazole in Healthy Female Subjects

Healthy Subjects | Pharmacokinetics | DDI (Drug-Drug Interaction)

Germany
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)

Healthy Subjects | Pharmacokinetics | EC905 | Multiple Dose

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Whether Food Has an Effect on the Uptake of Solifenacin and Tamsulosin When Administered in a Combination Tablet

Healthy Subjects | Pharmacokinetics | EC905

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effects of Single Ascending Doses of ASP1707 in Healthy Young Japanese Male Subjects

Healthy Subjects

United Kingdom

Clinical Trials Sponsored by Astellas Pharma Europe Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations